Jump to start of content

Complete requirements by 12/31/19 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/19 could result in a change to your certification status.

ABIM Scheduled Maintenance... Expand/Collapse the ABIM alert.

ABIM.org will be going through scheduled maintenance from 6 p.m. ET, Sat., 12/14 to 6 a.m. ET, Sun., 12/15. During this time, the ABIM Physician Portal will be unavailable.
We apologize for any inconvenience this may cause. Thank you for your patience.

Breadcrumb trail:

Gastroenterology Board

Expand All | Collapse All

Jane E. Onken, MD, Chair

Jane E. Onken, MDDr. Onken is an Associate Professor of Medicine, Division of Gastroenterology at Duke University Medical Center. She is Director of the Inflammatory Bowel Disease clinic at Duke and on faculty at the Duke Clinical Research Institute. She is board certified in Gastroenterology.

Dr. Onken is Chair of the American Board of Internal Medicine (ABIM) Gastroenterology Board and a member of the ABIM Council. She recently completed a three-year term as Chair of the Education and Training Committee of the American Gastroenterological Association (AGA). During that term, she served on the AGA's Leadership Cabinet, the Maintenance of Certification Task Force, and the Board of the Academy of Educators. She has chaired the AGA Training Subcommittee and been a member of the Graduate Training Examination Subcommittee. In 2013, she was selected to join the multi-society Oversight Working Network Committee, a group that designed the Entrustable Professional Activities currently in use by training programs in Gastroenterology. At Duke, she was recently elected for a fourth term to the University's Academic Council and has served on the Executive Committee of the Academic Council. Dr. Onken is a former program director for the Duke Gastroenterology Fellowship program. She is a member of the Leadership Board of the Triangle Chapter of the Crohn's and Colitis Foundation of America (CCFA) and is a recipient of the CCFA Premier Physician Award.

Dr. Onken received her undergraduate degree from Smith College and attended the George Washington University School of Medicine. She completed her house staff training in internal medicine at Duke University, followed by fellowship training in gastroenterology. She received a master's degree in health sciences from Duke in 2005.

As of May 2019, Dr. Onken reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to Duke University, from the following companies:

  • Boehringer Ingelheim, for a phase II/III clnical trial in patients with moderate to severe ulcerative colitis.
  • Janssen, for phase I clinical trial of ustekinumab in Crohn's disease.
  • Seres, for a clinical trial investigating fecal replacement for patients with mild-to-moderate ulcerative colitis.

Work funded by educational grants from industry, paid to Duke University, from the following companies:

  • Takeda, to create two dinner symposia updating community providers on irritable bowel disease, and two podcasts related to irritable bowel disease.

Dr. Onken serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Gastroenterological Association, Special Section Editor of Education and Training, receiving honoraria.

Kenneth R. DeVault, MD

Kenneth R. DeVault, MDDr. DeVault is Professor and Chair of the Department of Medicine at Mayo Clinic Florida. He is a member of the Executive Operating Team of Mayo Clinic in Florida. Dr. DeVault is board certified in Internal Medicine and Gastroenterology.

Prior to becoming Chair of Medicine, Dr. DeVault was Chair of the Division of Gastroenterology and Hepatology at the Mayo Clinic Florida from 2005-2010. He is a member of the American Board of Internal Medicine Gastroenterology Board. Dr. DeVault is a Fellow of and past president of the American College of Gastroenterology. He is also a member of the American Gastroenterological Association, American Society for Gastrointestinal Endoscopy and a fellow of the American College of Physicians.

Dr. DeVault conducts research on disorders affecting all aspects of the esophagus and has written more than 250 book chapters, abstracts, editorials and original articles on subjects ranging from treatment of GERD, dysphagia, esophagitis and Barrett's esophagus to laparoscopic anti-reflux surgery and managed care issues in the treatment of GERD. He also has interest in gastrointestinal health in the third world, improving professionalism in both trainees and practicing physicians and in the development of a diverse and effective health care work force.

He received his undergraduate degree from the University of Tennessee and his medical degree from the Bowman Gray School of Medicine at Wake Forest University. He completed his internship and residency in internal medicine at Vanderbilt University and completed a combined clinical and research fellowship at Jefferson Medical College.

As of April 2019, Dr. Devault reported no external relationships.

Hannah M. Herrington, MPH, CPH, CHES

Hannah M. Herrington, MPH, CPH, CHESMs. Herrington is currently a Health Communication Manager, consulting with government agencies and health industry clients on how to best engage people, patients, and caregivers in their health care, utilizing health literacy and clear communication best practices. She received her Master of Public Health, with a concentration in Behavioral Science and Health Education, from Rollins School of Public Health at Emory University in Atlanta, GA.

She has been working in the healthcare field for over a decade, from humanitarian organizations and insurance companies to corporate wellness firms. Ms. Herrington serves as a member of the American Board of Internal Medicine Gastroenterology Board. She was previously the Senior Manager of Patient Communications at the American Gastroenterological Association, setting up their first-ever patient engagement initiative, drafting and overseeing their 25-topic GI patient education digital library. Ms. Herrington is also certified in Public Health and a Certified Health Education Specialist.

Ms. Herrington has a personal connection to GI health as a long-time patient herself. She has had Crohn's disease for over 20 years, diagnosed as a teen. She's spent time educating herself about IBD research and new treatments, and staying involved in IBD advocacy and patient support organizations.

As of April 2019, Ms. Herrington reported the following external relationship:

Ms. Herrington reported health literacy and health communications consulting to ensure consumer understanding and general usability for websites or patient portals.

Sunanda V. Kane, MD

Sunanda V. Kane, MDDr. Kane is currently Professor of Medicine and Consultant in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minnesota. She is board certified in both Internal Medicine and Gastroenterology. Dr. Kane has a busy clinical practice, and she teaches and conducts research in the area of inflammatory bowel disease. Her main interests are in medication compliance and its effects on disease outcomes, as well as gender-specific issues.

Dr. Kane serves on the American Board of Internal Medicine (ABIM) Gastroenterology Board and formerly served on the ABIM Gastroenterology Self-Assessment Committee. She is the Director of the recently created Quality Council of the American College of Gastroenterology (ACG) and serves on the ACG Institute Board. She is also the Chair of Quality for the Division of Gastroenterology and Hepatology at Mayo Clinic. She was previously on the Board of Trustees for the ACG and served as Chair for the ACG Women's Committee as well as the Chair of the National Patient Education Committee for the Crohn's & Colitis Foundation of America.

Dr. Kane holds a medical degree from Rush Medical College in Chicago. She did her internship and residency at Rush-Presbyterian-St Luke's Medical Center in Chicago and a fellowship at the University of Chicago. She also holds a master's degree in epidemiology and biostatistics.

As of February 2019, Dr. Kane reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the Mayo Clinic, from the following companies:

  • AbbVie, for trials of adalimumab, upadacitinib, and rizankinumab for Crohn’s disease.
  • Celgene, ozanimod for Crohn’s disease.
  • Genentech, etrolizumab for Crohn’s disease.
  • Gilead, filgotininb for Crohn’s disease.
  • Janssen Pharmaceutica, for an open-label trial of ustekinumab for Crohn’s disease.
  • Takeda Pharmaceutical Company, for an open-label trial of vedolizumab for Crohn’s disease.

Service on a research-related expert panel or advisory board for the following company, with honoraria paid to Mayo Clinic:

  • Samsung Bioepis, to understand the role of biosimilars in the treatment of inflammatory bowel disease.
  • Janssen, to understand the role of ustekinumab in inflammatory bowel disease.
  • Spherix Health, to study management of inflammatory bowel disease in the real world.

Work as an author or editor for the following companies, with compensation as listed:

  • Mayo Clinic Scientific Press, receiving royalties for contribution to textbook Mayo Clinic Gastroenterology and Hepatology Board Review.
  • New England Journal of Medicine, receiving compensation for contributions to NEJM Journal Watch.

Dr. Kane serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American College of Gastroenterology, President, without compensation.

Funding for clinical trial expenses and salary support, paid to the Mayo Clinic, from the following organizations:

  • Crohn’s & Colitis Foundation of America, for participation as one site in a multi-center grant to study pregnant women with Crohn’s disease.
  • Crohn’s & Colitis Foundation of America, to support a study on the effects of medications on post-operative outcomes.
  • Crohn’s & Colitis Foundation of America, to support a study on diet in Crohn’s disease.

Dr. Kane serves as a member of the Board of Advisors for the Gastrointestinal Health Foundation, a non-profit organization that provides CME educational programs on topics related to gastrointestinal health, supported by educational grants from pharmaceutical companies.

Nancy S. Reau, MD

Nancy S. Reau, MDDr. Reau, who is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology, is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center.

She previously served as Assistant Professor of Medicine at Rush University in Chicago from 2002 to 2005. She became an Associate Professor of Medicine in 2010, Medical Director of Hepatology Clinical and Translational Research in 2015 and then joined Rush University Medical Center in 2015.

Dr. Reau's research interest is in viral hepatitis, both in drug development as well as utilization. She is currently a member of the American Board of Internal Medicine Gastroenterology Board, the American Association for the Study of Liver Diseases (AASLD) steering committee for the hepatitis C special interest group, and the AASLD/IDSA Practice Guidelines for hepatitis C. She served as Chair of the AASLD public policy committee. Additionally, Dr. Reau is a member of the American College of Gastroenterology women's training committee. She has been a member of the national board of directors of the American Liver Foundation (ALF) and served as the president of the Illinois chapter. She is currently co-Chair of the National ALF Medical Advisory Committee and serves on multiple advisory boards including Medscape and Medivo.

Dr. Reau received her bachelor's degree at Oberlin College in Oberlin, Ohio. She received her medical degree, cum laude, and completed a medicine residency and gastroenterology fellowship at The Ohio State University in Columbus, Ohio. She went to The Johns Hopkins Medical Center in Baltimore, MD, where she did her advanced transplant hepatology fellowship in 2001.

As of February 2019, Dr. Reau reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Chicago, from the following companies:

  • SHIRE, for NASH study.
  • GenFit, for NASH study.
  • Janssen, for a hepatitis B capsid assembly inhibitor study.
  • TARGET, for an observational trial on hepatitis C.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • Abbott, advising on development of hepatitis B and hepatitis C, receiving honoraria.
  • AbbVie, serving on a national advisory board for clinical development in hepatitis C, receiving travel reimbursement and honoraria.
  • Gilead, serving on a national advisory board for clinical development in hepatitis C, receiving travel reimbursement and honoraria.
  • Merck, advising on national and global development in hepatitis C, receiving travel reimbursement and honoraria.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following company, with compensation as listed:

  • Abbott, consulting on viral hepatitis education, receiving honoraria.

Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:

Dr. Reau develops educational content for continuing medical education on hepatitis C and provides an update to the American Association for the Study of Liver Disease for Clinical Care Options, receiving honoraria. Clinical Care Options is a medical education company that develops educational content and decision support tools.

Dr. Reau develops educational content for continuing medical education on hepatitis C receiving honoraria from the Chronic Liver Disease Foundation, which receives support from educational grants from multiple pharmaceutical companies

Dr. Reau serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Association for the Study of Liver Disease, Member of the Steering Committee for the Hepatitis C Special Interest Group, Editor-in-Chief of Clinical Liver Disease, receiving honoraria.
  • American College of Gastroenterology, Continuing Medical Education at courses, receiving honoraria and reimbursement for travel expenses.

Colleen M. Schmitt, MD

Colleen M. Schmitt, MDDr. Schmitt is a board certified internist and gastroenterologist. She has practiced as a consultant in gastroenterology in Chattanooga, Tennessee, with the multispecialty Galen Medical Group since 1993.

Currently, Dr. Schmitt is a member of the American Board of Internal Medicine Gastroenterology Board. She is a past President of the American Society for Gastrointestinal Endoscopy (ASGE) and has served on and chaired the Health and Public Policy Committee of the ASGE. She has co-chaired the Research Committee for the American College of Gastroenterology, and the ad hoc Committee on Outcomes Research for the ASGE. She served as Chief of the Gastroenterology division, the University of Tennessee College of Medicine, Chattanooga, where she was also Director of Clinical Research.

Dr. Schmitt has worked in health and policy at the local, state and national levels, and helped develop the Volunteers in Medicine Clinic, Chattanooga, where she has served on the Board, as well as on the Board of the Chattanooga & Hamilton County Medical Society.

Dr. Schmitt obtained her medical degree at the University of South Alabama, Mobile, and then completed her internship and residency in internal medicine at Beth Israel Hospital in Boston. She completed a fellowship in gastroenterology at Duke University Medical Center and a joint fellowship in health services research at the Durham VA Hospital, where she earned a master's degree in biometry and informatics.

As of March 2019, Dr. Schmitt reported the following external relationships:

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses:

  • Amsung
  • Acumen/Centers for Medicare and Medicaid Services
  • GI Quality Improvement Consortium (GIQuIC) Registry

Dr. Schmitt serves in a significant role with the following organizations, receiving reimbursement or compensation as listed:

  • American Society for Gastrointestinal Endoscopy, Professional Societies Relationship Working Group, Course Director, CRC Screening Working Group, MIPS/MACRA Working Group, receiving reimbursement for travel expenses and honoraria.
  • National ACO, receiving reimbursement for travel expenses and honoraria.
  • Chattanooga Hamilton County Medical Society, President, receiving reimbursement for travel expenses.

GI Quality Improvement Consortium (GIQuIC), Board member and Treasurer, receiving reimbursement for travel expenses.Dr. Schmitt is also a medical director for AMSURG Digestive Disorders Endoscopy Center.

Richard K. Sterling, MD

Dr. Sterling received his BS in Chemistry and Natural Science from Muhlenberg College (1982), a MA in Biochemistry from the University of Texas in Austin (1984), a MD from Jefferson Medical College in Philadelphia (1988) and a MSc in Biostatistics and Clinical Research from VCU (2007). After completing an internship and residency in Internal Medicine at Virginia Commonwealth University, he went on to complete a fellowship in Gastroenterology, Hepatology, and Nutrition at VCU which includes specialized training in Transplant Hepatology in 1994.

He is currently a VCU Hepatology Professor of Medicine in the Divisions of Gastroenterology, Hepatology, and Nutrition and Infectious Diseases, Section Chief of Hepatology and Medical Director of Viral Hepatitis and Transplant Hepatology Fellowship Director. He is board certified in Internal Medicine, Gastroenterology, and Liver Transplantation, and serves as a member of the American Board of Internal Medicine Gastroenterology Board. His research interest is in HIV-liver disease which is supported by several NIH grants. He is site Principle Investigator (PI) for the Hepatitis B Research Network and was PI for the HALT-C trial. Other research interests include biomarkers for non-invasive assessments of liver disease, viral hepatitis, and liver transplantation.

He has published over 200 papers and serves on several prominent committees in the American Gastroenterological Association (AGA), the American Association for the Study of Liver Diseases (AASLD), and the American College of Gastroenterology (ACG) and has served on study sections of the NIH. He is on several AASLD committees including the AASLD Transplant Hepatology Pilot Steering Committee, the Development Committee, the Education Committee, as well as on the Liver-Biliary Council of the AGA and has served as the ACG Governor for Virginia for six years.

As of January 2019, Dr. Sterling reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Virginia Commonwealth University, from the following companies:

  • Abbott, providing testing for an ancillary study to a National Institutes of Health Cooperative Agreement Award (Hepatitis B Research Network) and to an R01 research grant for novel hepatitis B assays, receiving salary support.
  • Gilead, supplying study drug for patients as part of a clinical trial for which he is a co-investigator.
  • Roche, providing test kits for hepatitis B testing in support for an R01 research grant.

Service on data and safety monitoring boards for the following companies, with compensation for travel expenses:

  • Baxter, for a trial using adenovirus to treat hemophilia.
  • Pfizer, for a HIV drug trial.

Work as an author or editor for following companies, with compensation as listed:

  • Steinberg Gastroenterology Board Review, receiving royalties for completed previous work.

Laura D. Wingate, BA

Laura D. Wingate, BAMs. Wingate is Senior Vice President, Education, Support, & Advocacy for the Crohn's & Colitis Foundation, where she oversees patient and professional education, state and federal advocacy, and support programming for the Foundation. She works in conjunction with the Crohn's & Colitis Foundation National Scientific Advisory Committees and numerous patient volunteers on developing all programs and resources.

Prior to this, Ms. Wingate was Director of Operations for Clown Care & Vaudeville Caravan Programs, where she worked for eight years in providing professional entertainers to pediatric and geriatric centers across the United States. She began her career at Memorial Sloan Kettering Cancer Center, where she advised and implemented quality improvement initiatives including the redesign of the outpatient center focused on streamlining the patient’s experience.

She currently serves as a member of the American Board of Internal Medicine Gastroenterology Board.

Ms. Wingate holds a bachelor's degree in arts, health and society from the University of Rochester, and has completed master’s degree coursework at New York University’s Robert F. Wagner Graduate School for Public Service.

As of March 2019, Ms. Wingate reported the following external relationships:

  • Crohn's and Colitis Foundation, Senior Vice President of Education, Support, Advocacy, receiving salary support.
  • Food and Drug Institute, Advisor, without compensation.